Locations:
Search IconSearch
May 23, 2024/Cancer/News & Insight

“Must See” Abstracts at 2024 ASCO Annual Meeting

Key research findings to watch

CAR T-cells

One of the most significant gatherings of oncology professionals is almost upon us. As you plan your time at ASCO®, keep an eye out for these top research studies highlighted by Cleveland Clinic leadership.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Time
9:00 AM – 12:00 PM CDT, June 1
Title
Study of ELU001, a C’Dot drug conjugate (CDC) targeting folate receptor α (FRα) overexpressing solid tumors
Abstract/Poster #
Abstract #TPS3173/ Poster #311b
Location
Hall A
9:00 AM-12:00 PM CDT, June 1
Title
Establishing a protocol to increase racial/ethnic minority enrollment on an active radiation oncology randomized clinical trial
Abstract/Poster #
Abstract #TPS1638/ Poster #509a
Location
Hall A
3:12 PM CDT, June 1
Title
Evaluation of a polygenic risk score as a predictor of early onset triple-negative breast cancer in Black women
Abstract/Poster #
Abstract #10501
Location
S100a
4:00 PM CDT, June 1
Title
Clinical behavior of breast cancer in young BRCA carriers and prognostic impact of the timing of genetic testing: Results from an international cohort study
Abstract/Poster #
Abstract #10503
Location
S100a
4:36 PM CDT, June 2
Title
Real-world outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with Richter transformation (RT) from the Center for International Blood and Marrow Transplant Research (CIBMTR)
Abstract/Poster #
Abstract #7010
Location
E450b
8:12 AM CDT, June 3
Title
Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC)
Abstract/Poster #
Abstract #4502
Location
Hall 81
10:21 AM CDT, June 3
Title
Tumor microbiome differences in early-onset versus average-onset pancreatic adenocarcinoma
Abstract/Poster #
Abstract #4016
Location
E451
1:30-4:30 PM CDT, June 3
Title
Effect of tumor burden on survival in patients with stage IV EGFR-mutant NSCLC receiving osimertinib monotherapy
Abstract/Poster #
Abstract #8611/ Poster #475
Location
Hall A
1:30 PM CDT, June 3
Title
Phase 1/2 study of the TGF-β-trap-enhanced oncolytic adenovirus, AdAPT-001, plus an immune checkpoint inhibitor for patients with immune refractory cancers
Abstract/Poster #
Abstract #2506
Location
Hall D2
10:21 AM CDT, June 4
Title
Assessing the prognostic value of transcriptomic data in multiple myeloma through machine learning methodologies
Abstract/Poster #
Abstract #7513
Location
S102

“These abstracts to be presented at the 2024 ASCO Annual Meeting represent collaborative work led by Cleveland Clinic oncologists, spanning a range of important areas of research, including early phase clinical trials of novel drugs, methods to increases diversity in clinical trials, studies of predictive factors of relapse, survival and response to therapies, real-world and patient-reported outcomes research, as well as the tumor microbiome,” says James Stevenson, MD.

Find more details about ASCO abstracts.

Advertisement

Related Articles

Pediatrician with child
Setting Standards in the Delivery of Pediatric Cancer Care

Leaders of the Pediatric Cancer Committee discuss new accreditation

Seth Rotz, MD, exams patient's throat during clinical exam
Study Reveals New Clues Into Childhood Cancer Survivors’ Increased Risk of Melanoma

Largest study of its kind identifies three treatment exposures that contribute to risk

Silhouettes of man and woman
February 7, 2025/Cancer/News & Insight
Pharmacokinetics of Many Anticancer Drugs Differ Among Sexes

Slower drug elimination from the body among females may impact safety and efficacy

Young patient with cancer
October 25, 2024/Cancer/News & Insight
Multidisciplinary Care Model Supports Young People with Cancer

Integrated program addresses growing need for comprehensive cancer care among adolescents, young adults and adults under 50 with early onset cancers

Genetic sequencing
September 26, 2024/Cancer
AI Can Help Find Trials for Patients with Rare Cancers

Study demonstrates potential for improving access

Dr. Holly Pederson
July 25, 2024/Cancer/Research
Evaluating Risk Scores for Triple-Negative Breast Cancer in Black Women (Podcast)

Polygenic risk score could help predict who will develop this aggressive breast cancer

Image showing Dr. Gupta
June 20, 2024/Cancer/Research
Trailblazing Urothelial Cancer Treatments (Podcast)

Platinum-eligible phase 3 trial of enfortumab vedotin and pembrolizumab yields ‘unprecedented data’

Patient taking medication
May 22, 2024/Digestive/Research
Study Finds No Connection Between OSMs and Increased Cancer Rates in IBD Patients

Reassuring results, but patient education is still important

Ad